FDA compliance and AI drive growth for Quotient
He will also be explaining how the company is expanding its Translational Pharmaceutics platform into new therapeutic areas like mRNA, and using AI to optimize...
Symbiosis unveils expanded facility at CPHI Milan 2024
The event provides a great platform for the company to present its newest addition—a 20,000 sq ft facility in Stirling, UK, which the company says...
Ardena expands bioanalytical and GMP services
The company explains attendees will gain insight into how Ardena’s innovations can streamline drug development for advanced therapies, particularly in oncology and specialized therapeutic areas. OSP...
Women in Science – SCIEX Rebekah Sayers
Find out all about her intriguing journey to where she is now in her role as marketing manager within small molecule omics at SCIEX. Could...
Optimizing patient recruitment for faster clinical trials
The success of these trials hinges on finding and enrolling the right patients in a timely manner. Eben Scanlon, chief customer officer at OneStudyTeam, has...
SK pharmteco invests $260M in small molecules
The expansion involves setting up a new facility, which is planned to begin operations in late 2026. The facility, which will include 300 new hires,...
LoQus23 raises £35M to advance Huntington’s disease therapy
UK-based company LoQus23 Therapeutics has announced the closing of a £35 million series A round to advance its pipeline of small molecule drugs. The financing...
Stevanato to launch Vertiva 10mL on-body system at CPHI 2024
The company says this new platform is specifically designed to administer large-volume injectable therapies, including highly viscous biological drugs, making it suitable for a wide...
Sequentia Biotech bags €10m for omics products
Sequentia will use the round winnings to speed up the market introduction of its cloud-based and microbiome-focused healthcare software MICK and scale up the development...
The impact of AI technology in pharmacovigilance
Eric Prugh is the chief product officer at Authenticx, a US-based company that recently launched an AI solution to detect adverse events in conversations to...
From philosophy to biochemistry – Women in Science
With a passion for problem-solving and sustainability, her journey into science began with a fascination for philosophy and the origins of life, ultimately leading her...
Pfizer withdraws sickle cell drug over safety
The withdrawal decision was prompted by clinical data indicating that the overall benefit of Oxbryta “no longer outweighs the risk” in its target patient population,...
AbbVie reports positive phase 3 results for Parkinson’s drug
The oral, specific dopamine agonist met its primary endpoint in the trial, which is the second of three phase 3 trials testing tavapadon for treatment...
Biohaven’s troriluzole shows promise in spinocerebellar ataxia
Biohaven, which spun out of Biohaven Pharmaceuticals in 2022 when its parent company was acquired by Pfizer, has had a number of setbacks in the...
Miplyffa bags FDA approval for ultra-rare disease
NPC is a progressive disease where the patient has a mutation in NPC1 or NPC2 – genes that are involved in the processing of cholesterol...
YPrime COO Alison O’Neill -‘pursue what you enjoy and be flexible’
She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this position, Alison oversees project management and...
Nura Bio secures $140M to advance lead drug to next trials
Nura Bio has announced the addition of $68 million to its series A financing, closing the round with a total of $140 million. The investment...
Insilico’s lead drug meets safety and efficacy goals in IPF trial
Insilico Medicine, a biotech company with offices in both China and the US, announced this week that its lead candidate drug had met its primary...
uMotif acquires ClinOne, integrates eConsent for clinical trials
Announced on September 4, 2024, this acquisition positions uMotif to enhance its existing capabilities by integrating ClinOne’s enterprise consent management, site productivity tools, and trial...
F2G raises $100M to advance olorofim after FDA rejection
Infections caused by Aspergillus species of mold are transmitted through inhalation and can lead to symptoms including hypersensitivity reactions and tissue damage. Invasive aspergillosis (IA)...